Fisetin and senolytics: what the trials show
Reviewed 22 sourcesPublished by PepVault
Every registered fisetin and dasatinib plus quercetin trial, its state and result, dated November 2026: what senolytics did in people, and what is still out.

- Last reviewed
- Sources
- 22
- Questions
- 8
- Compounds
- 2
The short answer
Senolytics are drugs meant to clear senescent cells, the worn-out cells that pile up with age. The best human result so far belongs to dasatinib plus quercetin: in a 2026 liver-fibrosis trial, 47% improved on biopsy against 7% on placebo. Fisetin extended life in one lab's mice but not in the NIA's, and none of its posted human results has beaten a control group yet.
Evidence: Human evidence is small: randomized and open-label trials of dasatinib plus quercetin of 5 to 60 people, and fisetin results posted on ClinicalTrials.gov; all lifespan data are in mice.

What are senolytics, and where does fisetin fit?
A senescent cell is one that has stopped dividing but refuses to die. It sits in the tissue and leaks inflammatory signals, and these cells build up with age. A senolytic is a drug that kills them selectively. The class was named in 2015, when a Mayo Clinic team found that senescent cells lean on survival pathways that healthy cells do not need, and that two existing drugs could switch those pathways off: dasatinib, a leukemia drug, and quercetin, a plant flavonoid10. Each worked on different cell types, so they were paired as D+Q.
Fisetin came next. In 2018 a screen of 10 flavonoids, run in senescent mouse and human cells, found fisetin the most potent senolytic of the set7. It is the compound sold as a supplement, which is why it gets most of the searches.
The schedule is the unusual part. Senescent cells take weeks to build back up, so the trials give a senolytic for two or three days and then stop for weeks, the "hit-and-run" pattern. D+Q leaves the body within hours: both drugs have elimination half-lives under 11 hours2.

Does fisetin extend lifespan?
In mice, one lab says yes and the stricter test says no. Fisetin given to old wild-type mice late in life lowered senescence markers, reduced age-related tissue damage and extended median and maximum lifespan7. Then the National Institute on Aging's Interventions Testing Program, which runs each compound at three sites in genetically mixed mice, fed fisetin and found no significant lifespan gain in males or females at the dose and schedule it used8.
D+Q has the stronger mouse record. Given intermittently to naturally aged mice, it eased physical decline and raised survival after treatment by 36%9.
Species note: every lifespan result on this page is in mice. No senolytic has been tested for lifespan in people, and none is approved for aging.
What did dasatinib plus quercetin do in people?
D+Q is the senolytic with published human results, and the newest is the strongest. In fibrotic fatty liver disease (MASH, liver inflammation with scarring), 31 people were randomized to D+Q or placebo, three days a week for three weeks, repeated over three cycles. On a second liver biopsy, scarring improved by at least one stage in 47% on D+Q against 7% on placebo, and the liver inflammation cleared in 53% against 7%1. Side effects were more frequent on D+Q (82% against 43%), and all of them passed on their own1.
| Trial | Who | What happened |
|---|---|---|
| Fatty liver with scarring, 2026, randomized, placebo1 | 31 adults | Scarring improved in 47% against 7% on placebo; inflammation cleared in 53% against 7%. |
| Diabetic kidney disease, 2019, open-label2 | 9 adults, average age 69 | Senescent cells in fat tissue fell within 11 days of one 3-day course, as did inflammatory blood markers such as IL-6. |
| Lung fibrosis, 2019, open-label3 | 14 adults | Walking distance, gait speed and chair stands improved; lung function did not change. |
| Lung fibrosis, 2023, randomized, placebo4 | 12 adults | Everyone finished every dose; function did not differ meaningfully from placebo in a trial too small to test it. |
| Bone, postmenopausal women, 2024, randomized5 | 60 women | The main bone-loss marker did not differ from control. A bone-building marker rose 16% against control at weeks 2 and 4. Women with the most senescent cells gained 2.7% bone density at the forearm. |
| Mild Alzheimer's, 2023, open-label6 | 5 adults | Dasatinib reached the spinal fluid in 4 of 5; quercetin was not found there. Memory and brain scans did not change over 12 weeks. |

Read the pattern: D+Q clears senescent cells in human tissue2, and the best result so far came where senescent cells drive the disease, a scarred liver1. In the bone trial the women who started with the most senescent cells were the ones who responded5, a hint that a senolytic helps most where there is most to clear. Open-label means everyone knew they were on the drug, so those results carry less weight than the placebo-controlled ones.
What did fisetin do in people?
Fisetin's senolytic trials have mostly reported to the registry, not to journals. ClinicalTrials.gov lists results for five of them, and none shows fisetin beating its comparison group on the main measure (one had no comparison group):
| Trial (registry number) | Who | Posted result |
|---|---|---|
| Bone, older women: the fisetin arm of the D+Q bone trial (NCT04313634)11 | 14 on fisetin, 30 untreated | The bone-loss marker rose a median 13.7% on fisetin and fell 7.7% in the untreated group: no sign of benefit. |
| Knee osteoarthritis (NCT04210986)12 | 34 fisetin, 40 placebo | Side effects in 28 against 33 people; CRP, a blood marker of inflammation, and a cartilage-breakdown marker did not differ from placebo over 12 months. |
| COVID-19 at home (NCT04771611)13 | 29 fisetin, 26 placebo | By day 60, 26 of 27 on fisetin and 22 of 24 on placebo had no limits, a draw; serious events 0 against 2. |
| COVID-19 in nursing homes (NCT04537299)14 | 20 adults | Stopped early for futility by its safety board and the NIA. |
| Carpal tunnel (NCT05416515)15 | 40 adults, no placebo | The symptom-and-function score fell 0.5 points on its 1-to-5 scale over 60 days. |

Two published trials did report a benefit, neither of them a test of clearing senescent cells. In stroke patients given a clot-dissolving drug, adding fisetin improved stroke scores in those treated late16. In a 44-man trial in obesity, the group taking 200 mg of fisetin a day without exercise saw the inflammatory markers IL-6 and TNF-alpha fall over 12 weeks17.
Which senolytic trials are still running?
On November 20, 2026, a registry search returns 38 trial records with fisetin as an intervention and 22 with dasatinib and quercetin2021. Most are small, and the larger ones report from 2027. The ones to watch:
| Trial | Compound | Size | State on Nov 20, 2026 |
|---|---|---|---|
| Frailty in older women and in older adults, Mayo (NCT03430037, NCT03675724) | Fisetin | 40 each | Enrolling by invitation; due November 2027 |
| Sepsis in people 65 and over, Minnesota (NCT05758246) | Fisetin, two doses | 220 | Recruiting; due June 2027 |
| Blood-vessel function in older adults, Colorado (NCT06133634, NCT07871162) | Fisetin | 70, then 136 | Active; the larger phase 2 not yet recruiting |
| Frailty in breast cancer survivors, UCLA (NCT05595499, NCT06113016) | Fisetin | 88 and 164 | Recruiting |
| Low-dose daily fisetin, Denmark (NCT07195318) | Fisetin 100 mg a day | 120 | Listed as recruiting; due date October 2026 passed |
| Daily against pulsed fisetin (NCT07918261) | Fisetin | 82 | Completed January 2024; no results posted |
| Bone with osteoporosis, Odense (NCT06018467) | D+Q, or nicotinamide riboside | 120 | Completed April 2026; no results posted |
| Frailty in HIV, NIAID (NCT07144293) | D+Q | 82 | Completed August 2026; no results posted |
| Early Alzheimer's, SToMP-AD (NCT04685590) | D+Q | 48 | Active, not recruiting |

What doses did the trials use?
These are the schedules researchers chose and monitored, set out to show what was studied, not a dose for any one person.
| Regimen | Amount | Schedule |
|---|---|---|
| Fisetin pulse, Mayo and Steadman trials1112 | About 20 mg per kg of body weight a day | 2 or 3 days in a row, repeated every 28 days |
| Colorado vascular trial22 | 2 mg per kg a day | Two 3-day courses, two weeks apart |
| Daily low-dose fisetin18 | 100 mg a day | 7 weeks |
| Fisetin with exercise17 | 200 mg a day | 12 weeks |
| D+Q, liver and lung trials13 | Dasatinib 100 mg with quercetin 1,000 to 1,250 mg | 3 days a week for 3 weeks |
| D+Q, kidney and bone trials25 | Dasatinib 100 mg with quercetin 1,000 mg | One 2- to 3-day course, or one every 28 days |
At 20 mg per kg, a 70 kg adult takes about 1,400 mg a day, far above anything in food. Dasatinib is a prescription cancer drug, approved for chronic myeloid leukemia and one form of acute leukemia; its label lists low blood counts, bleeding and fluid build-up, including fluid around the lungs, among its warnings19. Starting it outside a trial is a doctor's decision.
When to get help Fever, breathlessness, chest pain, or new bleeding or bruising during a dasatinib course is a reason to contact the prescribing clinician straight away19.
What do people notice on a senolytic pulse?
Commonly reported: fisetin taken as a few high-dose days a month, with nothing felt during or after.
On D+Q the trials recorded more. In the open-label lung trial the common complaints were breathing symptoms, skin irritation or bruising, and stomach discomfort, mostly mild to moderate3. In the placebo-controlled one, sleep problems and anxiety turned up in 4 of 6 people on D+Q and none on placebo4.
Since nothing is felt, a pulse is judged by numbers: a before-and-after hs-CRP test (the sensitive form of CRP, the inflammation marker the knee trial tracked12) and the dates of each course.
PepVault sets a pulse up as an oral cycle (for example 3 days on, 25 off), reminds you on each dose day and logs it, so the gap between courses is on record. Set reminders in PepVault
Its bloodwork log keeps hs-CRP beside your other markers, so a test before and after a course sits in one place. Log it in PepVault
So do senolytics work?
D+Q is the winner on the evidence. It clears senescent cells in human tissue2, and in a placebo-controlled trial it improved liver scarring in nearly half the people treated1. It has not shown a benefit for bone overall or for lung function, and it relies on a prescription leukemia drug.
Fisetin is the open question. The lab that found it showed longer life in mice7, the NIA's program did not8, and none of its posted human results shows a win over placebo or an untreated group11121314. The trials built to answer it, in frailty, blood vessels and sepsis, report from 2027. This page is dated so you can see when they land.
Sources
- Koning M et al. Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. Nat Metab. 2026. PubMed 42823536
- Hickson LJ et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019. PubMed 31542391
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019. PubMed 30616998
- Nambiar A et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial. EBioMedicine. 2023. PubMed 36857968
- Farr JN et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med. 2024. PubMed 38956196
- Gonzales MM et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med. 2023. PubMed 37679434
- Yousefzadeh MJ et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018. PubMed 30279143
- Harrison DE et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002, dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex. Geroscience. 2024. PubMed 38041783
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018. PubMed 29988130
- Zhu Y et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015. PubMed 25754370
- ClinicalTrials.gov NCT04313634. Targeting cellular senescence with senolytics to improve skeletal health in older humans (Mayo Clinic): posted results, accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT04210986. Senolytic drugs attenuate osteoarthritis-related articular cartilage degeneration (Steadman Philippon Research Institute): posted results, accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT04771611. COVFIS-HOME: fisetin in at-risk COVID-19 outpatients: posted results, accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT04537299. COVID-FIS: fisetin in older adults in nursing homes: posted results and reason stopped, accessed November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT05416515. FITCATS: fisetin to treat carpal tunnel syndrome: posted results, accessed November 20, 2026. clinicaltrials.gov
- Wang L et al. Fisetin prolongs therapy window of brain ischemic stroke using tissue plasminogen activator: a double-blind randomized placebo-controlled clinical trial. Clin Appl Thromb Hemost. 2019. PubMed 31434498
- Alipour M et al. 12-weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin-1 and inflammatory markers in men with obesity: a randomized controlled trial. J Int Soc Sports Nutr. 2026. PubMed 42218768
- Tavenier J et al. Low-dose fisetin supplementation and its association with chronic inflammation in middle-aged and older adults: study protocol for a triple-blind, randomised, placebo-controlled trial. Basic Clin Pharmacol Toxicol. 2026. PubMed 42633989
- SPRYCEL (dasatinib) tablets, prescribing information (E.R. Squibb & Sons). DailyMed, version of November 2, 2026: Indications and usage; Warnings and precautions. dailymed.nlm.nih.gov
- ClinicalTrials.gov: all studies with fisetin as an intervention, searched November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov: all studies with dasatinib and quercetin as interventions, searched November 20, 2026. clinicaltrials.gov
- ClinicalTrials.gov NCT06133634. Fisetin to improve vascular function in older adults (University of Colorado Boulder), accessed November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.